As of Apr 29
| -0.23 / -0.48%|
The 6 analysts offering 12-month price forecasts for Five Prime Therapeutics Inc have a median target of 46.50, with a high estimate of 52.00 and a low estimate of 39.00. The median estimate represents a -2.29% decrease from the last price of 47.59.
The current consensus among 7 polled investment analysts is to Buy stock in Five Prime Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.